Purpose: Sirolimus has potent anti-rejection activity as well as the ability to prolong allograft survival and reduce nephrotoxicity. This study was designed to evaluate the efficacy and safety of sirolimus in Korean de novo renal transplantation. Methods: We included 79 patients who received sirolimus at nine Korean transplantation centers in the intention-to-treat and valid-for-safety analyses. The study was an open, single treatment arm multicenter trial with 12 months of patient follow-up. Initially, patients received 2 mg of sirolimus (after 6 mg of loading does) with cyclosporine and steroids. Sirolimus was administered for up to 12 months. Antibody induction was not used. At 3 months after transplantation, cyclosporine was progressively withdrawn over 4 to 8 weeks while sirolimus was adjusted to obtain trough concentrations within 15∼30 ng/ml up to 6 months and concentrations within 12∼24 ng/ml between 7 and 12 months. Results: The proportion of patients who completed the 12-month sirolimus medication per protocol was 74.7% (59/79). Cyclosporine withdrawal was possible in 64 recipients (81.0%). Fifteen patients discontinued sirolimus before cyclosporine withdrawal, and 5 recipients did so after successful cyclosporine withdrawal. Most common causes of sirolimus discontinuation were graft rejection (n=8). Incidence of biopsy-proven acute rejection within 6 months after transplantation was 15.2%. Patient and graft survival rates at 12 months post transplantation were 97.5% and 96.2%, respectively. During the study period, three graft losses occurred by patient death. Conclusion: Based on this study, cyclosporine and sirolimus induction followed by cyclosporine withdrawal at 3 months post-transplant is considered to be efficient and safe after primary renal transplantation. (J Korean Surg Soc 2010;79:261-266)
Therefore, in this study, we evaluated the efficacy of SRLbased immunosuppression therapy after early CsA withdrawal, as assessed by the incidence of biopsy-proven acute rejection episodes at 6 months, the safety of SRL, and graft function and survival over 12 months after transplantation in primary renal transplantation recipients in Korea. USA) up to 6 months and within 12∼24 ng/ml between 7 and 12 months ( 
2) Efficacy assessments
The primary efficacy endpoint was the incidence of biopsy-proven acute rejection episode at 6 months after transplantation. Renal biopsy was taken when acute rejection was suspected. For patient management, the interpretation of the pathologist at each site was used to define acute rejection according to the Banff 97 criteria for classification. Secondary efficacy endpoints included graft function at 6 and 12 months after transplantation (as determined by serum creatinine and e-GFR by Nankivell equation (9)) and patients and graft survival at 6 and 12 months after transplantation. The analysis of the data was 
3) Safety assessment
Patients who received at least one dose of SRL were included in this analysis. All of the observed adverse events (AEs) were properly categorized, and then occurrence rates and confidence intervals were calculated. AEs were classified by using the Medical Dictionary for Regulatory Activities Table 1 . Among them, 47 (59.5%) were female, and 32 (40.5%) were male. All patients were Korean.
CsA withdrawal was initiated a mean of 96.1±14.2 days after transplantation, and 33.0±15.1 days were required to complete CsA withdrawal.
2) Dose and trough levels of immunosuppressive drugs
The mean daily dose and trough concentrations of SRL and CsA were summarized in Fig. 2 . One week after CsA withdrawal, the mean SRL trough level was 15.8±5.2 ng/ml.
At 4 weeks after CsA withdrawal, it was 16.2±4.2 ng/ml.
3) Efficacy evaluations
The incidence of biopsy-confirmed acute rejection episodes at 6 and 12 months after transplantation was 15.2% The patient and graft survival rate at 12 months after transplantation was 97.5% and 96.2% respectively.
4) Safety evaluation
All patients reported at least one episode of AE. Among them, 78.5% patients reported 143 episodes of infection.
The incidence of AEs related to the study drug was 91.1%, and infections related to the study drug were 46.8%. By system organ class using MedDRA 10.1, gastrointestinal disorders were most frequently reported in 66 patients (83.5%). The most frequently reported AE other than infection, was constipation (38.0%), serum cholesterol elevation (36.7%), and diarrhea (27.9%). Simple upper respiratory tract infection was the most common type of infection. SAEs were reported in 39 patients (49.4%). The most frequently reported SAEs were elevated serum creatinine concentration (12.7%), lymphocele (7.6%), herpes zoster infection (7.6%), and pulmonary infection (6.3%).
Seven SAEs (5 lymphoceles, 1 ventral hernia, and 1 wound seroma) with wound healing were reported, and the investigators concluded that only 5 SAEs were related to SRL.
Hematology and blood chemistry, lipid profile of patients are presented and summarized in Based on this study, CsA and SRL induction followed by CsA withdrawal at 3 months post-transplant is considered to be efficient and safe after primary renal transplantation.
SRL maintenance regimen has been shown to be an effective treatment for the prevention of renal acute rejection episodes in primary renal allograft recipients.
